U29-S02. Modification of oligonucleotides. (Remote) OUTSTANDING
Modification of oligonucleotides during and post synthesis to meet user requirements:
Modification of oligonucleotides during and post synthesis to meet user requirements:
Special nucleotides for oligonucleotide synthesis For those services identified as outstanding, at least 20% of their capacity is open under competitive access. See Annex 1 of ACCESS PROTOCOL (provided by Nanbiosis) for details on % of openness for each service
Synthesis of oligonucleotides at various different scales (100 microg to 5 mg) and purification using HPLC and/or desalting.
Conventional TEM provides structural information of samples prepared to electron transparency in the sub-nanometer range. Once prepared, many biological samples, including bacteria, viruses, yeasts, cells, and tissue sections can be characterized using TEM. Moreover, TEM can be used to characterize many other types of material such as substrates or nanoparticles making it a highly versatile technique.
Applications:
>> Cellular characterization
>> Tissues characterization
>> Biomaterials characterization
>> Macromolecular complexes characterization
CAbS offers personalized development of immunoassays. Antibodies and other necessary immunoreagents can be synthesized.
The development of the immunoassay includes different stages:
The purification of the antibodies includes the isolation of the antibody from the serum (polyclonal antibodies) or culture supernatant from hybridoma cell lines (monoclonal antibodies). The services offers previous advise on the different possibilities for purification according to the needs of the user.
The methods of purification that we offer vary from crude methods (precipitation of the proteins from the sample including any antibody present) to general purification (purification by affinity of certain classes of antibodies without taking account of the specificity to the antigen) to specific (purification by affinity of the antibodies which join specifically to a definite antigen).
Hybridoma cell culture in ultralow serum medium. We use CELLine™ Bioreactor Technologys to produce monoclonal antibodies.
The mAb development contains the following phases: